register

News & Trends - MedTech & Diagnostics

MTAA’s landmark agreement delivers medical device savings for millions of Australians

Health Industry Hub | February 3, 2020 |

The price of thousands of medical technologies treating heart and lung disease, diabetes, bone cancer, eye trauma, severe arthritis and more will be slashed for millions of Australians with private health insurance from Saturday 1 Feb 2020, saving patient lives, livelihoods and wallets.

The price cuts are thanks to the Medical Technology Association of Australia’s landmark agreement with Federal Health Minister Greg Hunt in 2017, which is on track to save $1.1 billion off the cost of medical devices by 2022. 

MTAA CEO Ian Burgess said patients continued to get “more for less”, with price drops for about 7,000 individual types and brands of medical technologies used in millions of procedures in the private system each year, including:

“This agreement with government continues to help more Australians access more medical technology at less cost. That is what I call a win-win-win for patients, taxpayers and industry.

“This announcement also debunks the long-held claim that the cost of individual medical technologies continue to rise, when the vast majority are actually falling in price.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

“This is further evidence that when governments work with the medical technology sector, patients get a good deal more.”

Over 3 million medical devices were used to treat Australians with private health insurance last year alone.

Mr Burgess said just like advancements in medicines, medical technology was evolving and becoming as much about improving lives, not just saving them.

“Two of the biggest contributors to Australia’s ill-health are inactivity and isolation – and the two are often linked, particularly as we get older.

“Increasingly medical technology is being used not just to save lives, but keeping Australians more mobile, social, and now, working, for longer, which are all essential to the future health of our ageing population and economy.

“These medical technologies are also continuing to improve patient recovery and operating times, for less cost, meaning better outcomes for the health system and the budget.”

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting your organisation to Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with proven digital media solutions developed by industry for industry.


News & Trends - MedTech & Diagnostics

Health insurers clash with government decision on GUIs, prompting threat of premium hikes

Health insurers clash with government on GUIs decision, prompting threat of premium hikes

Health Industry Hub | May 2, 2024 |

MedTech & Diagnostics News: A warning of potential increases in health insurance premiums for 15 million Australians has been issued […]

More


News & Trends - MedTech & Diagnostics

Catheter ablation underused in atrial fibrillation despite proven efficacy

Catheter ablation underused in atrial fibrillation despite proven efficacy

Health Industry Hub | May 2, 2024 |

MedTech & Diagnostics News: A new study highlights that nearly half of all patients hospitalised for atrial fibrillation (AF) in […]

More


News & Trends - Biotechnology

How prepared are we for the next pandemic?

How prepared are we for the next pandemic?

Health Industry Hub | May 2, 2024 |

Biotech News: The Melbourne biotechnology community came together for a symposium hosted by BioMelbourne and mRNA Victoria, featuring specialists in […]

More


News & Trends - Pharmaceuticals

AbbVie's JAK inhibitor triumphs: Head-to-Head trial reveals superior outcomes in atopic dermatitis

AbbVie’s JAK inhibitor triumphs: Head-to-Head trial reveals superior outcomes in atopic dermatitis

Health Industry Hub | May 2, 2024 |

Pharma News: In a head-to-head trial, AbbVie’s JAK inhibitor Rinvoq (upadacitinib) showed superior efficacy over Regeneron and Sanofi’s Dupixent (dupilumab) […]

More


This content is copyright protected. Please subscribe to gain access.